Literature DB >> 10596842

Kallikrein-kinin in infection and cancer.

H Maeda1, J Wu, T Okamoto, K Maruo, T Akaike.   

Abstract

This review article describes the mechanism of enhancement of vascular permeability in infectious disease and cancer. This phenomenon is primarily mediated by bradykinin, nitric oxide and other unique vascular mediators. They are highly intermingled with each other in these disease states. Furthermore, these mediators are elicited in various in vivo settings most frequently induced by bacterial proteases, and indirect or direct activation of kallikrein-kinin cascade at one or more steps. The key steps involve bacterial proteases or cellular components including lipopolysaccharides. Thus, the use of appropriate protease inhibitors or antagonists, or scavengers in the case of nitric oxide, superoxide or peroxynitrite, are anticipated to attenuate the clinical manifestation induced by such mediators. It also explained that fluid accumulation in ascitic or pleural compartments in the case of carcinomatosis in terminal cancer patients can be largely attributed to bradykinin or related mechanism. Systemic bacterial dissemination is also facilitated by bradykinin, or suppressed by kinin antagonists as well as by the inhibition of kinin production, respectively. Thus, control of the level of such vascular mediators appears important both in infectious disease and in cancer. alpha1-Protease inhibitor, which inhibits neutrophil elastase, is inactivated by oxidative metabolites such as superoxide and peroxynitrite, and this effect activates matrix metalloproteinases. This indicates that oxidative stress activates proteolytic potential, and thus accelerates the degenerative process upon infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10596842     DOI: 10.1016/s0162-3109(99)00104-6

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  15 in total

Review 1.  Cross-talk between the complement and the kinin system in vascular permeability.

Authors:  Fleur Bossi; Ellinor I Peerschke; Berhane Ghebrehiwet; Francesco Tedesco
Journal:  Immunol Lett       Date:  2011-07-06       Impact factor: 3.685

2.  Passive targeting of nanoparticles to cancer: A comprehensive review of the literature.

Authors:  Remon Bazak; Mohamad Houri; Samar El Achy; Wael Hussein; Tamer Refaat
Journal:  Mol Clin Oncol       Date:  2014-07-23

3.  Blockade of gC1qR/p33, a receptor for C1q, inhibits adherence of Staphylococcus aureus to the microvascular endothelium.

Authors:  Shneh Sethi; Mathias Herrmann; Jonas Roller; Lutz von Müller; Ellinor I Peerschke; Berhane Ghebrehiwet; Irma Bajric; Michael D Menger; Matthias W Laschke
Journal:  Microvasc Res       Date:  2011-04-22       Impact factor: 3.514

4.  Effects of transforming growth factor-beta in the development of inflammatory pseudotumour-like lesions in a murine model.

Authors:  Luciana Doria Guariniello; Mariangela Correa; Miriam Galvonas Jasiulionis; Joel Machado; José Antônio Silva; João Bosco Pesquero; Célia Regina Whitaker Carneiro
Journal:  Int J Exp Pathol       Date:  2006-06       Impact factor: 1.925

5.  Specificity of a Vibrio vulnificus aminopeptidase toward kinins and other peptidyl substrates.

Authors:  Gary P Richards; Alberto Nuñez
Journal:  J Bacteriol       Date:  2006-03       Impact factor: 3.490

Review 6.  Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?

Authors:  Yuko Nakamura; Ai Mochida; Peter L Choyke; Hisataka Kobayashi
Journal:  Bioconjug Chem       Date:  2016-09-02       Impact factor: 4.774

Review 7.  Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting.

Authors:  Khaled Greish; Jun Fang; Takao Inutsuka; Akinori Nagamitsu; Hiroshi Maeda
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 8.  Humoral innate immune response and disease.

Authors:  Stephanie N Shishido; Sriram Varahan; Kai Yuan; Xiangdong Li; Sherry D Fleming
Journal:  Clin Immunol       Date:  2012-06-18       Impact factor: 3.969

Review 9.  Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting.

Authors:  Hiroshi Maeda
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2012       Impact factor: 3.493

10.  Enhancement of blood-tumor barrier permeability by Sar-[D-Phe8]des-Arg9BK, a metabolically resistant bradykinin B1 agonist, in a rat C6 glioma model.

Authors:  Ronie Cleverson Cardoso; Bruno Lobão-Soares; Marino Muxfeldt Bianchin; Carlos Gilberto Carlotti; Roger Walz; Márcio Alvarez-Silva; Andréa Gonçalves Trentin; Mauro Nicolau
Journal:  BMC Neurosci       Date:  2004-09-30       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.